Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...

Teva Pharmaceuticals and Alvotech have announced the US launch of Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® ...

Johnson & Johnson (NYSE:JNJ) is reportedly suing Samsung Bioepis for breach of contract related to the launch of a biosimilar ...

Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) and Sanofi SA (NASDAQ:SNY) presented new, detailed results from the RELIEVE ...

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today presented new, detailed results from the RELIEVE UCCD phase 2b study of duvakitug, a human IgG1-λ2 ...

Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Coming in first on the list of Top 25 Pharma Companies US Rx is AbbVie, reaching $41,857m in US Rx revenue in 2023 and ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.